Medindia

X

Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008

Thursday, February 7, 2008 General News J E 4
Advertisement
WEIFANG, China, Feb. 6 ShengtaiPharmaceutical, Inc. (OTC Bulletin Board: SGTI.OB) ("Shengtai Pharmaceutical"or "the Company"), a leading manufacturer and distributor of high-quality,pharmaceutical grade glucose products in China and glucose and starch productsthat serve as raw materials for food, beverage and industrial production,today announced that it will conduct a conference call at 9:00 a.m. EasternTime on Friday, February 15, 2008 to discuss the second quarter results offiscal year 2008.

Shengtai Pharmaceutical's Chief Financial Officer, Mr. Yizhao Zhang willbe participating in the conference call. The Company plans to make an earningsannouncement prior to the call.

To participate in the live conference call, please dial the followingnumber five to ten minutes prior to the scheduled conference call time:866-800-8648. International callers should dial 617-614-2702. When prompted bythe operator, mention Conference Passcode 835 628 35.

If you are unable to participate in the call at this time, a replay willbe available for 14 days starting on Friday, February 15 at 11:00 a.m. EasternTime. To access the replay, dial 888-286-8010, international callers shoulddial 617-801-6888, and enter the passcode 497 603 34.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary ShengtaiHolding, Inc. (SHI), a New Jersey corporation, and the Chinese operatingcompany of Weifang Shengtai Pharmaceutical Co., Ltd., is a leadingmanufacturer and supplier of glucose products, which include pharmaceuticalgrade glucose used for medical purposes, and glucose and cornstarch productsfor the food and beverage industry and for industrial production in China. Formore information about Shengtai Pharmaceutical, Inc. please visithttp://www.shengtaipharmaceutical.com.

Safe Harbor Statement

Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: Certain statements in this press release and oral statements made bythe Company, constitute forward-looking statements for purposes of the safeharbor provisions under The Private Securities Litigation Reform Act of 1995.These statements include, without limitation, statements regarding our abilityto prepare the company for growth, the Company's planned capacity expansion in2008 and predictions and guidance relating to the Company's future financialperformance. We have based these forward-looking statements largely on ourcurrent expectations and projections about future events and financial trendsthat we believe may affect our financial condition, results of operations,business strategy and financial needs but they involve risks and uncertaintiesthat could cause actual results to differ materially from those in theforward-looking statements, which may include, but are not limited to, suchfactors as unanticipated changes in product demand especially in thepharmaceutical industry, pricing and demand trends for the Company's products,changes to government regulations, risk associated with operation of theCompany's new facilities, risk associated with large scale implementation ofthe company's business plan, the ability to attract new customers, ability toincrease its product's applications, cost of raw materials, downturns in theChinese economy, and other information detailed from time to time in theCompany's filings and future filings with the United States Securities andExchange Commission. Investors are urged to consider these factors carefullyin evaluating the forward-looking statements herein and are cautioned not toplace undue reliance on such forward-looking statements, which are qualifiedin their entirety by this cautionary statement. The forward-looking statementsmade herein speak only as of the date of this press release and the Companyundertakes no duty to update any forward-looking statement to conform thestatement to act
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Alticor's 2007 Global Sales Top $7 Billion
S
Lotus Pharmaceuticals, Inc. Achieves Significant M...